Gastrokine 1 protein is a potential theragnostic target for gastric cancer
- 557 Downloads
Gastrokine 1 (GKN1) plays important roles in maintaining mucosal homeostasis, and in regulating cell proliferation and differentiation. Here, we determined whether GKN1 is a potential theragnostic marker for gastric cancer.
We identified GKN1 binding proteins using the protein microarray assay and investigated whether GKN1 is one of the exosomal cargo proteins by western blot, immunoprecipitation, and immunofluorescent assays. Cell proliferation and apoptosis were analyzed by MTT, BrdU incorporation, flow cytometry, and western blot assays. We further validated the functional relevance of exosomal GKN1 in MKN1-injected xenograft mice. The possibility of serum GKN1 as a diagnostic marker for gastric cancer was determined by ELISA assay.
In protein microarray assay, GKN1 binding to 27 exosomal proteins was clearly observed. GKN1 was expressed in exosomes derived from HFE-145 gastric epithelial cells by western blot and immunofluorescent assays, but not in exosomes from AGS and MKN1 gastric cancer cells. Exosomes carrying GKN1 inhibited cell proliferation and induced apoptosis in both AGS and MKN1 cells, and exosomes carrying GKN1-treated nude mice-bearing MKN1 xenograft tumors exhibited significantly reduced tumor volume and tumor weight. Silencing of clathrin markedly down-regulated the internalization of exosomal GKN1. Interestingly, serum GKN1 concentrations in patients with gastric cancer were significantly lower than those in healthy individuals and patients with colorectal and hepatocellular carcinomas.
The GKN1 is secreted and internalized in the gastric epithelium by exosome-driven transfer, which inhibits gastric tumorigenesis and supports the clinical application of GKN1 protein in gastric cancer diagnosis and treatment.
KeywordsGKN1 Exosome Theragnosis Gastric cancer
Human gastrokine 1 (GKN1), made of 185 amino acid residues, is a stomach-specific protein which is produced by gastric mucus-secreting cells, stored in cytoplasmic granules, and secreted with mucus onto the apical cell surface [1, 2]. We and others previously showed that inactivation of GKN1 as a tumor suppressor is one of the leading causes of gastric cancer [3, 4, 5]. Although GKN1 plays important roles in maintaining mucosal integrity and homeostasis, and in regulating cell proliferation and differentiation [6, 7, 8], no study has yet investigated how GKN1 secretion and internalization take place in gastric mucosal epithelium.
Recently, it has been reported that intercellular communication through the transfer of extracellular vesicles (EVs) plays an important role in a range of physiological processes including intercellular exchange of proteins and RNA [9, 10] and immune regulation [10, 11] in multicellular organisms. EVs are small vesicles released by donor cells that can be taken up by recipient cells . EVs that are derived from multi-vesicular bodies are referred to as exosomes . Exosomes can carry cargo from their originating cells as functional messenger RNA, microRNA, or proteins [14, 15]. Many EV proteins have been shown to interact with membrane receptors on target cells [16, 17] and are usually taken up into endosomal compartments via endocytosis [18, 19, 20]. To understand the emerging roles of exosomes in normal physiological processes and in diseases, it is important to identify the molecular mechanisms that underlie exosome release by donor cells and exosome internalization by target cells.
Here, we provided the first evidence that human gastric epithelial cells naturally secrete and internalize GKN1 as an exosomal protein and that GKN1 protein may be a potential diagnostic marker and therapeutic target for gastric cancer.
Cell culture and transfection of c-Myc
Cell culture and transfection of c-Myc were described in the supplementary Methods.
Identifying the GKN1-binding proteins through HuProtTM microarrays
Identifying the GKN1-binding proteins through HuProtTM microarrays were described in the supplementary Methods.
We washed exosomes derived from AGS and MKN1 cells treated with recombinant GKN1 protein (rGKN1) with PBS and lysed at 4 °C with PBS, pH 7.2 containing 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 10 mMNaF, 1.0 mM NaVO4, and 1% protease inhibitor cocktail (Sigma, St. Louis, MO, USA), as described previously . Equal protein aliquots (1.0 mg) were immunoprecipitated with 2.0 µg of antibodies to GKN1 (Abcam, Cambridge, UK), COMT and YWHAZ (Genetex, CA, USA) plus protein A/G-agarose (Santa Cruz Biotechnology), as described previously .
Exosome isolation and labeling were described in the supplementary Methods.
Trypsin digestion assay
To determine the localization of GKN1 in exosomes, we subjected purified exosomes from HFE-145 cells (35 µg proteins in 7 µL of PBS) to lipid membrane lysis by 1% Triton X-100 for 30 min at 4 °C, as previously described . A detailed description for trypsin digestion assay is in the supplementary Methods.
Immunoblot, immunofluorescent, and transmission electron microscopy (TEM) studies
Immunoblot, immunofluorescent, and transmission electron microscopy assays were described in the supplementary Methods.
Real-time RT-PCR analysis was described in the supplementary Methods.
Measurement of cell viability and apoptosis
Measurement of cell viability and apoptosis were described in the supplementary Methods.
Flow-cytometry analysis of cell cycle
Flow-cytometry analysis of cell cycle was described in the supplementary Methods.
Chromatin immunoprecipitation (ChIP)
To assess the c-Myc and NKX6.3 binding in the promoter regions of NKX6.3 and GKN1, respectively, we performed ChIP assays using the Thermo Scientific Pierce Agarose ChIP kit (Thermo Scientific Pierce), as described previously . We amplified the DNA by PCR using primers for the NKX6.3 promoter, as described in supplementary Table S1. We separated amplification products on a 2% agarose gel.
In vivo assay
Animal experiments were approved and performed in accordance with the Institutional Animal Care and Use Committee at the Ajou University School of Medicine (Suwon, Gyeonggi-do, Korea). A detailed description for in vivo assay was in the supplementary Methods.
We obtained written informed consent from all participants in accordance with the Declaration of Helsinki. The study was approved by the Institutional Review Board of The Catholic University of Korea, College of Medicine (MC16SISI0132). There was no evidence of familial cancer in any of the patients. A detailed description for serum samples was in the supplementary Methods.
We used Student’s t test to analyze the effects of GKN1 on cell viability and proliferation, and Chi-square test to compare GKN1, Ki-67, and Annexin V staining patterns. We performed all experiments in duplicate to verify the reproducibility of the findings. Data are expressed as means ± SD from two independent experiments. We considered a P value less than 0.05 to be the limit of statistical significance. To further evaluate the diagnostic usefulness of the markers based on dichotomous classification, we conducted receiver operating characteristic (ROC) curve analysis. An ROC curve is a plot of the true-positive fraction versus the false-positive fraction evaluated for all possible cut-off point.
Identification of GKN1-binding proteins
In protein microarray assay, we clearly observed that recombinant GKN1 (rGKN1) bound to 27 exosomal proteins; the GKN1-interacting exosomal proteins are presented in Fig. 1a. Of these, we verified the interaction between GKN1 and COMT and between GKN1 and YWHAZ using co-immunoprecipitation analysis (Fig. 1b).
Detection of GKN1 in exosomes derived from gastric cell lines
To investigate whether GKN1 is spontaneously secreted and internalized as an exosomal protein, we isolated exosomes from the cultured supernatants from HFE-145, AGS, and MKN1 gastric cells. In transmission electron microscopy (TEM) analysis, structurally intact exosomes, which revealed the presence of vesicles ranged in size from 30 to 200 nm, could be detected (Fig. 1c). Expectedly, exosomes derived from HFE-145 immortalized gastric epithelial cells expressed GKN1, whereas exosomes from AGS and MKN1 gastric cancer cells did not (Fig. 1d). When we treated AGS and MKN1 cells with rGKN1, the expression of GKN1 was present mainly in the exosomes and scant or absent in exosome-free media and exosome-free whole cell lysate (Fig. 1d). Of two exosomal protein markers, we detected TSG101 in both the purified exosomes and exosome-free whole cell lysates, whereas we found CD81 expression only in exosomes (Fig. 1d).
Next, to reveal whether or not GKN1 protein is present in exosomes, we performed trypsin digestion assays with and without Triton X-100, followed by western blot analysis . When we treated the exosomes with trypsin in the absence of Triton X-100, GKN1 was protected from trypsin-dependent enzymatic degradation. However, GKN1 was completely degraded in the presence of both trypsin and Triton X-100 (Fig. 1e), suggesting that GKN1 protein is present in exosomes.
Measurement of cell proliferation and cell death
To identify the biological effects of exosomal GKN1 on cell viability and proliferation, we treated HFE-145, AGS and MKN1 cells with exosomes derived (1) from AGS and MKN1 cells non-treated and treated with rGKN1, and (2) from HFE-145 cells that originally expressed GKN1. Treatment with GKN1-negative exosomes derived from AGS and MKN1 cancer cells markedly increased cell viability in HFE-145, AGS and MKN1 cells, whereas GKN1-positive exosomes derived from same cells significantly inhibited cell viability and proliferation in AGS and MKN1 cells (Fig. 2a, b and supplementary Fig. 1a, b). Compared with rGKN1, exosomal GKN1 dramatically inhibited cell viability and proliferation in AGS and MKN1 cancer cells (Fig. 2c and supplementary Fig. 1c, d). In cell cycle analysis, exosomes derived from HFE-145 cells significantly decreased S phase and increased G1 and G2/M phase cell populations (Fig. 2d). Consistently, GKN1-positive exosomes derived from AGS cells treated with rGKN1 inhibited cell cycle progression in AGS and MKN1 cells (supplementary Fig. 2a). For G1 phase arrest, exosomal GKN1 increased expression of negative regulators of cell cycle such as p53 and p21 and down-regulated expression of positive regulators of cell cycle such as cdk4 and cyclin D (Fig. 2e). For G2/M arrest, GKN1 down-regulated expression of p-cdc2, cdc25c, and cyclin B proteins in HFE-145, AGS, and MKN1 cells (Fig. 2e).
In addition, GKN1-positive exosomes derived from HFE-145 cells and AGS cells treated with rGKN1 significantly increased apoptotic AGS and MKN1 cells (Fig. 2f and supplementary Fig. 2b). Expression of cleaved caspase-3 and -8 increased markedly, whereas there were no significant changes in BAX or BCL2 expression (Fig. 2e). Taken together, it is likely that upon cellular internalization, exosomal GKN1 interacts with cytoplasmic proteins that inhibit proliferation and induce apoptosis of gastric epithelial cells.
To further confirm that exosomal GKN1 inhibits cell proliferation, we performed MTT and BrdU incorporation assays after treatment with GW4869 (sigma), an inhibitor of exosome biogenesis/release. In MKN1 cells, GW4869 markedly decreased exosomal protein concentration (Fig. 2g). As expected, rGKN1 significantly decreased cell viability and proliferation in MKN1 cells, whereas treatment with both rGKN1 and GW4869 did not (Fig. 2h and supplementary Fig. 1e, f). Thus, exosomal form of GKN1 protein may function as a tumor suppressor and serve as a therapeutic target of gastric cancer.
GKN1 positive exosomes suppress tumor growth in vivo
To investigate the effect of the tumor suppressive function of GKN1-positive exosomes in vivo, we intravenously injected the exosomes with or without GKN1 into the mice with MKN1 xenograft tumors subcutaneously six times in 2 weeks (n = 7 mice/group). The serum GKN1 concentration in GKN1-positive exosome-treated group was significantly higher relative to other groups (Fig. 3a). As expected, treatment with GKN1-positive exosomes significantly inhibited tumor growth by day 25 as compared to PBS- and control exosome-treated mice (Fig. 3b). Consistently, mean weight of harvested tumors (Fig. 3c) treated with GKN1-positive exosomes was significantly lower than that of tumors treated with control exosomes (P = 0.017) and PBS (P = 0.026) (Fig. 3d). Animal activity and change of body weight were not different among each treatment group during 4 week observation period (data not shown).
In immunofluorescent analysis, tumors from mice treated with GKN1-positive exosomes showed significantly increased GKN1 expression in the cytoplasm of cancer cells, but PBS- and control exosome-treated tumors did not (Fig. 3e). In addition, growth fraction with Ki-67 staining was significantly decreased in tumors treated with GKN1-positive exosomes (P = 0.018), whereas apoptosis with Annexin V staining was significantly higher compared with other groups (P = 0.007) (Fig. 3e). Statistically, expression of GKN1 was inversely correlated with Ki-67 expression and positively correlated with Annexin V staining in tumors treated with GKN1-positive exosomes (P = 0.003 and P = 0.004, respectively; Fig. 3f). Western blot analysis showed that expression of CDK4/6, cyclins A, B, and D, and p-cdc2 was reduced, while cleaved caspase-3, -8, and PARP, p53, p16, and p21 were markedly increased in tumors treated with GKN1-positive exosomes (Fig. 3g). These results suggested that GKN1 can be effectively delivered to xenograft tumors and further support that exosomal form of GKN1 may be a therapeutic target of gastric cancer.
Internalization of exosomes into gastric cancer cells depends on clathrin
Next, we evaluated how exosomes containing GKN1 protein internalize into gastric cancer cell lines. As shown in Fig. 4a, AGS and MKN1 cells transfected with siClathrin showed a notable reduction of clathrin expression. When we treated AGS and MKN1 cells with PKH26-positive exosomes that carried GKN1 (Fig. 4b), these exosomes were clearly localized in the cytoplasm of AGS and MKN1 cells (Fig. 4c). However, clathrin knockdown dramatically inhibited the internalization of PKH26-positive exosomes into the AGS and MKN1 cells’ cytoplasm (Fig. 4c). In these cells, expression of both GKN1 and CD81 was significantly reduced in membrane and not detected in the cytoplasm (Fig. 4d).
Measurement of GKN1 protein levels in sera is useful for gastric cancer diagnosis
To confirm whether GKN1 protein is present in culture media and human sera, we measured GKN1 concentrations in culture media from HFE-145 cells and human sera by ELISA, after incubation at 70 °C for 10 min. Under non-heating conditions, we did not detect GKN1 in either total media, exosomes and exosome-depleted media from HFE-145 cells (Fig. 5a) or whole serum, exosomes, and exosome-free sera (Fig. 5b). However, the GKN1 concentrations in total media, exosomes, and exosome-depleted media treated at 70 °C for 10 min were 1.13 ± 0.06, 1.08 ± 0.1 and 0.05 ± 0.04 ng/ml, respectively (Fig. 5a). In ten healthy individuals, the GKN1 concentrations in whole serum and exosomes treated with heat were 6.53 ± 0.58 and 6.24 ± 0.55 ng/ml, respectively (Fig. 5b). In ten gastric cancer patients, they were 3.58 ± 0.54 and 3.28 ± 0.82 ng/ml in whole serum and exosomes, respectively (Fig. 5b), suggesting that the majority of serum GKN1 is enriched within exosomes. Thus, we analyzed GKN1 concentrations in the whole sera from 100 healthy subjects and 245 patients with gastric, colorectal cancers or hepatocellular carcinomas after heating at 70 °C for 10 min.
As shown in Fig. 5c, there was a slight association between serum GKN1 levels in healthy individuals and aging, but there was no statistical significance (P = 0.338). In addition, there was no difference in serum GKN1 levels between males and females (P = 0.074). Interestingly, individuals with atrophic gastritis with and without intestinal metaplasia (IM) showed serum GKN1 concentrations that were lower than those in subjects without gastritis, but significantly higher than those in patients with gastric cancer (Fig. 5d).
The concentrations of GKN1 in whole sera of 100 healthy subjects and 150 patients with gastric cancer were 6.35 ± 0.82 and 3.50 ± 0.57 ng/ml, respectively (Fig. 5e), indicating that serum GKN1 levels in gastric cancer patients were significantly lower than those in healthy individuals (P < 0.0001). Furthermore, GKN1 levels in serum of gastric cancer patients were significantly lower than those of hepatocellular carcinoma (6.26 ± 0.95 ng/ml) and colorectal cancer (6.07 ± 0.92 ng/ml) (Fig. 5e). Notably, the serum GKN1 concentration discriminated patients with gastric cancer from healthy individuals without atrophic gastritis and subjects with atrophic gastritis without and with IM with the area under the ROC curve (AUC) values of 1.0000, 1.0000, and 0.9964, respectively (Fig. 5f). When we analyzed the ability of the serum GKN1 levels to discriminate the patients with gastric cancer from the patients with hepatocellular and colorectal carcinomas, the GKN1 concentration in whole sera predicted the risk of gastric cancer with AUC values of 0.9938 and 0.9987, respectively (Fig. 5g).
Based on the depth of invasion, gastric cancer is classified into early (EGC) and advanced (AGC). Notably, serum GKN1 concentrations in the patients with EGC (3.75 ± 0.47 ng/ml) were significantly higher than those in the patients with AGC (3.38 ± 0.58 ng/ml) (P < 0.001) (Fig. 5h). However, serum GKN1 concentrations in patients with EGC were lower than those tested in subjects with atrophic gastritis and IM (P < 0.001) (Fig. 5h). In addition, using GKN1 levels in whole sera, EGC patients can be distinguished from (1) healthy individuals (AUC: 1.00), (2) individuals with atrophic gastritis (AUC: 1.00), and (3) individuals with atrophy and IM (AUC: 0.98) (Fig. 5i).
Exosomes from gastric cancer cells down-regulate NKX6.3 and GKN1 expression in gastric epithelial cells
Next, we investigated whether exosomes derived from cancer cells down-regulate GKN1 expression in normal gastric epithelial cells. Interestingly, exosomes released from AGS and MKN1 cancer cells markedly inhibited the expression of both GKN1 and NKX6.3, which is a transcriptional factor of GKN1 , at mRNA and protein levels and increased expression of c-Myc and Max proteins in HFE-145 cells (Fig. 6a, b). In addition, we observed that the expression levels of c-Myc and Max in exosomes were higher in AGS and MKN1 cancer cells than in HFE-145 cells (Fig. 6c, d). Consistent with this result, ectopic c-Myc expression in HFE-145 cells also increased expression of Max protein and induced loss of GKN1 and NKX6.3 expression (Fig. 6e).
Next, we attempted to examine whether c-Myc is a transcriptional repressor of NKX6.3. Expectedly, ectopic expression of c-Myc in HFE-145 cells increased the binding activity of c-Myc to the upstream sequences of NKX6.3 and dramatically inhibited NKX6.3 binding to GKN1 promoter region (Fig. 6f). Thus, we conclude that c-Myc in exosomes derived from gastric cancer cells inhibits GKN1 expression in surrounding non-neoplastic gastric epithelial cells, and subsequently induces low serum GKN1 concentration.
Exosomal GKN1 does not affect cell viability and function of white blood cells
We further examined the possibility that exosomes that carry GKN1 could modulate cell viability and function of lymphocytes, monocytes, and macrophages. Interestingly, exosomes derived from HFE-145 cells bound to the membrane of THP-1 monocyte and U937 macrophage, but not Jurkat T cells, in immunofluorescent assay (Fig. 7a). GKN1 was expressed in the membrane fraction of THP-1 monocyte and U937 macrophage (Fig. 7b). However, the cell viability and expression levels of cytokines were not changed (Fig. 7c, d).
It is well known that GKN1 is packaged within secretary granules and predicted to have a secretory signal peptide [2, 25, 26]. For autocrine and paracrine functions, GKN1 must be internalized by gastric epithelial cells. However, current literature indicates neither GKN1 receptors nor GKN1 secretion and internalization pathways. Here, we aimed to determine whether GKN1 is secreted and internalized in gastric epithelial cells as an exosomal protein.
Here, we found that rGKN1 interacts with 27 exosomal proteins (Fig. 1a). Notably, exosomes from HFE-145 immortalized gastric epithelial cells expressed the GKN1 protein, but exosomes from AGS and MKN1 gastric cancer cells did not (Fig. 1b). These data are consistent with evidence showing that GKN1 was reduced or lost in gastric cancer [3, 27, 28]. In addition, GKN1 appears to be localized exclusively in exosomes (Fig. 1d, e), suggesting that GKN1 may be secreted into extracellular space as one of exosomal cargo proteins.
Because our previous study showed that rGKN1 significantly inhibits gastric cancer cell viability , we hypothesized that biological effects of GKN1 may be induced by exosome-mediated autocrine and paracrine transfer. Previous studies have demonstrated that cancer cell-derived exosomes inhibit tumor cell apoptosis and induce cell proliferation [29, 30]. Consistently, in this study, we found that GKN1-negative exosomes derived from AGS and MKN1 cancer cells increased cell viability and proliferation in HFE-145, AGS, and MKN1 cells. In contrast, GKN1-positive exosomes markedly inhibited cell viability and cell proliferation (Fig. 2a, b) and the effects of exosomal GKN1 on cell proliferation and apoptosis were stronger than those of rGKN1 (Fig. 2c). Consistent with the previous results [5, 28, 31], exosomal GKN1 induced G1 and G2/M arrests and apoptosis by regulating expression of proteins related to cell cycle and apoptosis (Fig. 2d–f and supplementary Fig. 2). In addition, GW4869, an inhibitor of exosome biogenesis/release, dramatically suppressed the effects of GKN1 on cell growth (Fig. 2h). In the nude mouse xenograft model, exosomal GKN1 significantly suppressed the growth of subcutaneous transplanted tumors of MKN1 cells by inhibiting cell proliferation and inducing apoptosis (Fig. 3). These findings strongly suggest that secreted exosomal GKN1 may be internalized into gastric epithelial cells and thereby alter a set of signaling pathways involved in regulation of cell growth and apoptosis. Because exosomes have limitless therapeutic potential for the treatment of cancer , it is plausible that modulating exosomes that carry GKN1 and stimulating its anti-cancerous effects could significantly impact the development of novel gastric cancer treatments, which will ultimately achieve the goal of gastric cancer prevention and remission.
For these phenotypic effects to occur, exosomes that carry GKN1 need to be fused with gastric epithelial cell membranes and be taken up into cells. EVs are usually taken up into endosomal compartments via endocytosis [18, 19, 20], and EV uptake is most likely dependent on the signaling status of recipient cells and the protein complement of the vesicle . Because the internalization of various cargo proteins and lipids from the mammalian cell surface occurs through clathrin and lipid-raft endocytic pathway , we treated AGS and MKN1 cells with rGKN1 after silencing clathrin with siClathrin. Interestingly, internalization of exosomes that carry GKN1 was dramatically inhibited in clathrin-silenced AGS and MKN1 cells (Fig. 4b, c), suggesting that clathrin-mediated endocytosis may be the main pathway for internalization of GKN1-positive exosomes into gastric epithelial cells. Although the mechanism that underlies fusion and uptake of these exosomes to the gastric epithelium remains to be clearly identified, we here provide direct evidence that GKN1 can induce autocrine and paracrine signaling through exosome exchange in gastric epithelial cells. Additional characterization of the pathways of internalization of GKN1-positive exosomes will elucidate the mechanisms of exosome-mediated therapeutic targets.
Recently, Villano et al. reported that GKN1 mRNA in sera is not an informative biomarker for this cancer . Here, to investigate whether GKN1 protein is present in sera as an exosomal protein, we analyzed GKN1 concentrations in 10 sera with and without heating at 70 °C for 10 min. Expectedly, we detected GKN1 in whole sera and serum exosomes, and its levels in exosomes reached nearly the similar to those of whole serum in both healthy subjects and gastric cancer patients (Fig. 5a, b). Thus, we conclude that vast majority of serum GKN1 is present within exosomes and that the protein could be delivered to non-gastric tissues as circulating exosomes.
Next, to evaluate the diagnostic value of serum GKN1, we examined GKN1 concentrations after heating at 70 °C for 10 min, in whole sera from 100 healthy subjects and 245 patients with gastric, colorectal, and hepatocellular carcinoma. Interestingly, GKN1 levels in the sera of gastric cancer patients were significantly lower than those in the sera of healthy subjects and the patients with hepatocellular and colorectal carcinomas (P < 0.0001; Fig. 5e). Notably, the serum GKN1 levels discriminated the patients with gastric cancer from healthy subjects and patients with hepatocellular and colorectal carcinomas (Fig. 5g). In addition, GKN1 concentrations in whole sera discriminated the patients with EGC from healthy individuals without atrophic gastritis and subjects with atrophic gastritis without and with IM (Fig. 5i). EVs protect their cargo from the attack of nuclease and proteases . EVs are well suited for biomarker analyses that may increase sensitivity and/or specificity [35, 36]. Thus, we conclude that GKN1 protein in serum may be an informative diagnostic biomarker for gastric cancer. Future studies with large populations are strongly needed to verify these initial observations.
These observations that serum GKN1 concentrations were lower in patients with gastric cancer prompted us to examine if cancer-derived exosomes inhibit the GKN1 expression in surrounding non-neoplastic gastric epithelial cells. In HFE-145 cells, exosomes released from AGS and MKN1 cancer cells had the potential to inhibit both GKN1 and NKX6.3 expression at mRNA and protein levels (Fig. 6a, b) by overexpression of c-Myc and Max (Fig. 6b). Consistent with the report that cancer exosomes alter the transcriptomes of target cells and stimulate non-tumorigenic epithelial cells to form tumors , it is most likely that exosomes derived from gastric cancer cells inactivate gastric tumor suppressors NKX6.3 and GKN1 in surrounding non-neoplastic gastric epithelial cells and subsequently decrease serum GKN1 concentrations. Additional studies are required to verify that cancer-derived exosomes instigate the normal cells to participate in progression of gastric cancer.
Because we detected GKN1 in human sera, we examined whether exosomes carrying GKN1 have an influence on white blood cells. GKN1-positive exosomes derived from HFE-145 cells were detected onto plasma membranes of THP-1 monocytes and U937 macrophages (Fig. 7a, b). However, no significant effect of exosomal GKN1 on cell viability and cytokine expression was seen in these cells (Fig. 7c, d). Thus, we can speculate that exosomal GKN1 may be used as a therapeutic target for gastric cancer without hematologic side effects.
In summary, an important observation of this study is that GKN1 was secreted to extracellular space as an exosomal cargo protein and was internalized through clathrin-mediated endocytosis. Exosomal GKN1 inhibited cell proliferation and induced apoptosis in gastric cancer cells and xenograft tumors. In addition, GKN1 concentrations in the sera of patients with gastric cancer were significantly lower than those in healthy subjects and patients with hepatocellular and colorectal carcinomas (P < 0.0001), suggesting that serum GKN1 may be an informative biomarker for the diagnosis of gastric cancer. Finally, we provided the first evidence that human gastric epithelial cells naturally secrete and internalize GKN1 as an exosomal protein and that GKN1 may be a potential diagnostic and therapeutic target for achieving gastric cancer remission.
This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2015R1A2A2A01002531 to W.S.P) and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI17C0364 to H.H). We thank Dr. SeongYeob Ryu, Department of Gastroenterologic Surgery, Chonnam National University Hwasun Hospital, 160, Ilsim-ri, Hwasun-eup, Hwasun-gun, Jeollanam-do, 519–809, Korea, for providing the gastric cancer samples with clinical information.
JHY and IHH performed the majority of experiments, analyzed the data, interpreted the data, funding acquisition and contributed to writing the manuscript. OK writing review and edited the manuscript. AH and STD provided the HFE-145 cells before publication. SWN and JYL writing review and edited the manuscript and helped in the interpreted the data. HH and WSP conceived the project, interpreted the data, funding acquisition and wrote the manuscript.
Compliance with ethical standards
Conflict of interest
The authors have declared no conflicts of interest. Dr. Park reports grants from The Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2015R1A2A2A01002531 to W.S.P), grants from The Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI17C0364 to H.H), during the conduct of the study; In addition, Dr. Park has a patent Diagnosis of gastric cancer using gastrokine 1 protein within blood pending, and a patent Anti-cancer composition including exosomal GKN1 protein pending.
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent to be included in the study, or the equivalent, was obtained from all patients. For studies with animals, all institutional and national guidelines for the care and use of laboratory animals were followed.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.